All In Biotech

Drug Trial Radar · NCT05239728

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Mar 15, 2022

Primary completion

Oct 28, 2026

Study completion Sep 28, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).

Conditions

  • Carcinoma, Renal Cell

Interventions

  • BelzutifanDrug

    Three 40 mg tablets given as a single oral 120 mg dose.

  • PembrolizumabBiological

    400 mg via IV infusion

  • PlaceboDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS)Time frame: Up to approximately 54 months

Locations

285 sites in 32 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix ( Site 3554)

    Phoenix, Arizona

  • City of Hope Comprehensive Cancer Center ( Site 3567)

    Duarte, California

  • Moores Cancer Center-Clinical Trials Office- Genitourinary ( Site 3516)

    La Jolla, California

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 3520)

    Los Angeles, California

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3518)

    Orange, California

  • Stanford Cancer Center ( Site 3523)

    Palo Alto, California

  • University of Colorado Anschutz Medical Campus ( Site 3514)

    Aurora, Colorado

  • Intermountain Health St. Mary's Regional Hospital ( Site 3562)

    Grand Junction, Colorado

  • Georgetown University Medical Center ( Site 3534)

    Washington D.C., District of Columbia

  • University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 3517)

    Miami, Florida

  • Moffitt Cancer Center ( Site 3540)

    Tampa, Florida

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 3515)

    Marietta, Georgia

  • Parkview Research Center at Parkview Regional Medical Center ( Site 3526)

    Fort Wayne, Indiana

  • Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center- GU Oncology ( Site 3549)

    Baltimore, Maryland

  • Massachusetts General Hospital ( Site 3571)

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 3572)

    Boston, Massachusetts

  • Dana-Farber Cancer Institute-GU ( Site 3505)

    Boston, Massachusetts

  • Cancer and Hematology Centers of Western Michigan ( Site 3502)

    Grand Rapids, Michigan

  • Washington University-Internal Medicine/Oncology ( Site 3531)

    St Louis, Missouri

  • St. Vincent Frontier Cancer Center-Research ( Site 3506)

    Billings, Montana

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 3550)

    Omaha, Nebraska

  • Englewood Hospital and Medical Center ( Site 3557)

    Englewood, New Jersey

  • Rutgers Cancer Institute of New Jersey ( Site 3541)

    New Brunswick, New Jersey

  • Monter Cancer Center ( Site 3560)

    Lake Success, New York

  • Icahn School of Medicine at Mount Sinai ( Site 3539)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 3568)

    New York, New York

  • University of Rochester Medical Center ( Site 3528)

    Rochester, New York

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3507)

    Columbus, Ohio

  • MidLantic urology ( Site 3501)

    Bala-Cynwyd, Pennsylvania

  • Fox Chase Cancer Center-GU Oncology ( Site 3535)

    Philadelphia, Pennsylvania

  • Sanford Cancer Center ( Site 3551)

    Sioux Falls, South Dakota

  • The West Clinic, PLLC dba West Cancer Center ( Site 3522)

    Germantown, Tennessee

  • Urology Associates ( Site 3512)

    Nashville, Tennessee

  • UT Southwestern Medical Center ( Site 3529)

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center-Urology ( Site 3569)

    Houston, Texas

  • Inova Schar Cancer Institute ( Site 3525)

    Fairfax, Virginia

  • Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 3524)

    Seattle, Washington

  • Blacktown Hospital ( Site 0002)

    Blacktown, New South Wales, Australia

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 0003)

    Macquarie University, New South Wales, Australia

  • Tamworth Hospital-North West Cancer Centre ( Site 0006)

    North Tamworth, New South Wales, Australia

Showing 40 of 285 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.